• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Report: Sponsors will boost productivity, control R&D costs in 2015

Report: Sponsors will boost productivity, control R&D costs in 2015

January 9, 2015
CenterWatch Staff

Drug developers will implement strategies over the next year to improve clinical study performance to help control R&D costs and boost overall productivity, while increasing their focus on the development of cost-effective therapies that can help lower healthcare spending, according to the Tufts Center for the Study of Drug Development (CSDD).

“The key challenge for drug sponsors, policy makers and payers is to balance the need for new, innovative medicines with the equally pressing need to bring health care spending under control,” said Kenneth I. Kaitin, Tufts CSDD director. “But developing products that can treat complex diseases is expensive, as it now costs nearly $2.6 billion to develop and gain marketing approval for a new prescription drug.”

He added that drug sponsors looking for the most promising returns on investment have been transitioning from a high-volume, low-margin business model to a low-volume, high-margin model by directing a growing share of their resources toward development of precision medicines, specialty pharmaceuticals and orphan drugs.

However, many of these narrowly targeted products now in development may encounter strong resistance when they reach the market over the next several years, from payers who are increasingly seeking lower-priced therapeutic alternatives, he said.

Kaitin made his comments in connection with the release of the Tufts CSDD Outlook 2015 report on pharmaceutical and biopharmaceutical trends. The report also noted:

• Drug and biologics developers will expand their investment in new cancer therapies as a consequence of advances in the scientific understanding of the molecular basis of human cancers and cancer immunotherapy and its role in resistance.

• The FDA will respond to Congressional calls for improved clinical trial efficiency by supporting initiatives, such as the Lung Cancer Master Protocol, that create a single clinical trial infrastructure for testing several drugs simultaneously.

• Biosimilars are poised to have a significant impact on the U.S. and E.U. markets, with monoclonal antibodies (mAb) constituting the biggest target for developers; U.S. approval of a relatively large number of biosimilars is likely within one to three years.

• Adoption of simple (e.g., early futility, sample size re-estimation) and more sophisticated (e.g., dose response, randomization ratios) adaptive clinical trial designs will accelerate as functions within sponsors vie to increase data quality and program success rates.

Upcoming Events

  • 24May

    Powering an Effective Oversight Strategy with Clinical and Operational Insights

  • 25May

    2022 WCG Avoca Quality & Innovation Summit: Own the Future

  • 28Jun

    Effective Root Cause Analysis and CAPA Investigations for the Life Sciences

  • 16Oct

    WCG MAGI's Clinical Research Hybrid Conference - 2022 West

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • Protocol-360x240.png

    Avoid Deviations by Making Protocol Review a Team Effort

  • SelectionProcess-360x240.png

    Give Us a Voice: Sites Clamor for a Say on Vendor Selection

  • Convince-360x240.png

    Use Data and Details to Convince Site Leadership to Add Staff

  • AsktheExpertsBadge-360x240.png

    Ask the Experts: Listing Trial Staff and Others on the Statement of Investigator

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell My Personal Information

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2022. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing